Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Multiple Myeloma 11Recurrence 8Lymphoma, Large B-Cell, Diffuse 6Sezary Syndrome 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Leukemia 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Diseases 1Stomach Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1

Interventions

Octreotide 3Capecitabine 3Temozolomide 2Everolimus 2Bortezomib 2vatalanib 1romidepsin 1regorafenib 1pazopanib 1pasireotide 1motesanib diphosphate 1fluorodopa F 18 1batifiban 1Thalidomide 1Streptozocin 1Sorafenib 1Solutions 1Saline Solution 1Panobinostat 1Melphalan 1Leucovorin 1Irinotecan 1Injections 1Gefitinib 1Fluorouracil 1Cisplatin 1Biological Therapy 1Bevacizumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Insulinoma × Panobinostat × Clear all
NCT01056601 2017-12-28

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
7 enrolled 8 charts
EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡